A Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Oral Doses of GS-4571 in Healthy Participants, Multiple Ascending Oral Doses of GS-4571 in Nondiabetic Obese Participants and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM), and to Evaluate the Effect of Food and an Acid-Reducing Agent on Pharmacokinetics of GS-4571
Latest Information Update: 08 May 2025
At a glance
- Drugs GS 4571 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Gilead Sciences
Most Recent Events
- 13 Sep 2024 Status changed from not yet recruiting to recruiting.
- 27 Aug 2024 New trial record